Robbins LLP Files Class Action Against Inovio Pharmaceuticals

Lawsuit alleges Inovio misled investors about manufacturing issues with its CELLECTRA device.

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

Robbins LLP has filed a class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) on behalf of investors who purchased the company's securities between October 10, 2023 and December 26, 2025. The lawsuit alleges that Inovio failed to disclose manufacturing deficiencies with its CELLECTRA device, which caused delays in submitting the INO-3107 BLA to the FDA and reduced the likelihood of the drug receiving accelerated or priority review.

Why it matters

Inovio is a biotechnology company focused on DNA medicines, and the CELLECTRA device is a key component of its drug delivery system. Allegations of manufacturing issues and misleading investors about regulatory timelines could significantly impact the company's future prospects and shareholder value.

The details

According to the complaint, Inovio failed to disclose that: (i) manufacturing for its CELLECTRA device was deficient; (ii) as a result, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024 as initially projected; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; and (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated.

  • On August 8, 2024, Inovio issued a press release reporting a full-year delay in submitting the INO-3107 BLA to the FDA due to a "manufacturing issue" with the CELLECTRA device.
  • On December 29, 2025, Inovio announced that the FDA had accepted the INO-3107 BLA on a standard rather than accelerated review timeline, as the company did not submit adequate information to justify eligibility for accelerated approval.

The players

Inovio Pharmaceuticals, Inc.

A biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV).

Robbins LLP

A law firm recognized as a leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing.

Got photos? Submit your photos here. ›

What’s next

Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by April 7, 2026.

The takeaway

This case highlights the importance of biotechnology companies being transparent with investors about manufacturing issues and regulatory timelines, as any perceived misleading information can significantly impact shareholder value.